论文部分内容阅读
目的分析重组人干扰素α2b阴道泡腾胶囊联合宫颈电切术治疗宫颈上皮内瘤样病变(CIN)伴高危型人乳头瘤病毒(HR-HPV)感染的临床效果。方法选取76例CIN伴HR-HPV感染患者随机分为研究组和对照组各38例,对照组患者于月经结束后3~7 d时采用宫颈电切术治疗,研究组患者联合采用宫颈电切术与重组人干扰素α2b阴道泡腾胶囊治疗,1~12个月进行随访。结果治疗后研究组患者阴道出血量、阴道出血时间、阴道排液量、阴道排液时间少于对照组患者,差异有统计学意义(P<0.05);研究组患者4周内创面愈合率28.95%高于对照组患者的10.53%,8周内愈合率15.79%低于对照组患者36.84%,差异均有统计学意义(P<0.05);治疗后6个月及12个月时研究组患者的HPV-DNA转阴率81.58%及89.47%高于对照组患者的57.89%及68.42%,差异有统计学意义(P<0.05)。治疗前两组患者IL-6、TNF-α水平差异无统计学意义(P>0.05);治疗后研究组患者IL-6水平高于对照组患者,TNF-α水平低于对照组患者,差异有统计学意义(P<0.05)。研究组患者宫颈管狭窄发生率5.26%及宫颈息肉样增生发生率0.00%低于对照组患者的23.68%及21.05%,差异有统计学意义(P<0.05)。结论联合应用宫颈电切术及重组人干扰素α2b阴道泡腾胶囊治疗CIN伴HR-HPV疗效显著,可减少术后阴道出血量及排液量,加速创面愈合,促使HPV-DNA转阴,改善炎症因子水平,降低并发症发生率。
Objective To analyze the clinical efficacy of recombinant human interferon α 2b vaginal effervescent capsules combined with cervical resection for the treatment of cervical intraepithelial neoplasia (CIN) with high-risk human papillomavirus (HR-HPV) infection. Methods Totally 76 patients with CIN with HR-HPV infection were randomly divided into study group and control group, 38 cases in each group. Patients in control group were treated with cervical electrotomy 3 ~ 7 days after the end of menstruation. The patients in study group were treated with cervical electrovaporization Intraoperative and recombinant human interferon α2b vaginal effervescent capsules for treatment, 1 to 12 months for follow-up. Results After treatment, the vaginal bleeding volume, vaginal bleeding time, vaginal discharge volume and vaginal discharge time in the study group were less than those in the control group (P <0.05). The wound healing rate in the study group was 28.95 % Was higher than 10.53% of the control group, and the healing rate in 15 weeks was lower than that in the control group (15.79% vs 36.84%, P <0.05). After 6 months and 12 months, the study group The HPV-DNA negative rates were 81.58% and 89.47% higher than 57.89% and 68.42% respectively in the control group, with significant difference (P <0.05). There was no significant difference in the levels of IL-6 and TNF-α between the two groups before treatment (P> 0.05). After treatment, the level of IL-6 in study group was higher than that in control group, and the level of TNF-α was lower than that in control group There was statistical significance (P <0.05). The incidence of cervical stenosis and the incidence of cervical polyp hyperplasia in study group were 5.26% and 0.006%, respectively, which were significantly lower than those in control group (23.68% and 21.05%, respectively) (P <0.05). Conclusions The combined application of cervical resection and recombinant human interferon α2b vaginal effervescent capsules treatment of CIN with HR-HPV significant effect, can reduce postoperative vaginal bleeding and drainage volume, accelerate wound healing, prompting HPV-DNA negative, improve Inflammatory factor levels, reduce the incidence of complications.